Literature DB >> 12603205

Contrasting alloreactive CD4+ and CD8+ T cells: there's more to it than MHC restriction.

Keri L Csencsits1, D Keith Bishop.   

Abstract

Surface expression of CD4 or CD8 is commonly used to identify T-cell subsets that recognize antigen presented by class II MHC or class I MHC, respectively. This holds true for T cells that respond to allogeneic MHC molecules that are directly recognized as foreign, as well as peptides from allogeneic MHC molecules that are indirectly presented by self MHC molecules. CD4 or CD8 expression was initially believed to define cytokine secreting helper T cells or cytotoxic cells, respectively. However, this association of phenotype and function is not absolute, in that CD4+ cells may possess lytic activity and CD8+ cells secrete cytokines, notably IFNgamma. Recently, additional fundamental differences in the immunobiology of these T-cell subsets have been identified. These include differences in costimulatory requirements, cytokine responsiveness, cytokine production, cell survival, and the maintenance of memory. This review will survey these differences, emphasizing alloreactive T-cell responses as well as relevant observations that have been made in other systems.

Entities:  

Mesh:

Year:  2003        PMID: 12603205     DOI: 10.1034/j.1600-6143.2003.00036.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  14 in total

1.  Interferon gamma licensing of human dendritic cells in T-helper-independent CD8+ alloimmunity.

Authors:  Roxane Lemoine; Florence Velge-Roussel; Florence Herr; Romain Felix; Hubert Nivet; Yvon Lebranchu; Christophe Baron
Journal:  Blood       Date:  2010-07-19       Impact factor: 22.113

2.  Complement regulates CD4 T-cell help to CD8 T cells required for murine allograft rejection.

Authors:  Mark Vieyra; Staci Leisman; Hugo Raedler; Wing-Hong Kwan; Min Yang; Michael G Strainic; M Edward Medof; Peter S Heeger
Journal:  Am J Pathol       Date:  2011-06-23       Impact factor: 4.307

3.  T-bet Promotes Acute Graft-versus-Host Disease by Regulating Recipient Hematopoietic Cells in Mice.

Authors:  Jianing Fu; Yongxia Wu; Hung Nguyen; Jessica Heinrichs; Steven Schutt; Yuejun Liu; Chen Liu; Junfei Jin; Claudio Anasetti; Xue-Zhong Yu
Journal:  J Immunol       Date:  2016-02-22       Impact factor: 5.422

Review 4.  Current and future approaches for control of graft-versus-host disease.

Authors:  John Koreth; Joseph H Antin
Journal:  Expert Rev Hematol       Date:  2008-10       Impact factor: 2.929

5.  Cytotoxic effector function of CD4-independent, CD8(+) T cells is mediated by TNF-α/TNFR.

Authors:  Jason M Zimmerer; Phillip H Horne; Lori A Fiessinger; Mason G Fisher; Thomas A Pham; Samiya L Saklayen; Ginny L Bumgardner
Journal:  Transplantation       Date:  2012-12-15       Impact factor: 4.939

Review 6.  Graft-versus-host disease.

Authors:  James L M Ferrara; John E Levine; Pavan Reddy; Ernst Holler
Journal:  Lancet       Date:  2009-03-11       Impact factor: 79.321

7.  CD8+ Th17 mediate costimulation blockade-resistant allograft rejection in T-bet-deficient mice.

Authors:  Bryna E Burrell; Keri Csencsits; Guanyi Lu; Svetlana Grabauskiene; D Keith Bishop
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

Review 8.  Pathophysiology of acute graft-versus-host disease: recent advances.

Authors:  Yaping Sun; Isao Tawara; Tomomi Toubai; Pavan Reddy
Journal:  Transl Res       Date:  2007-07-03       Impact factor: 7.012

9.  Intracellular MHC class II controls regulatory tolerance to allogeneic transplants.

Authors:  Christian LeGuern; Yoshinobu Akiyama; Sharon Germana; Katsunori Tanaka; Luis Fernandez; Yoshiko Iwamoto; Stuart Houser; Gilles Benichou
Journal:  J Immunol       Date:  2010-01-25       Impact factor: 5.422

10.  Glucocorticoid-induced TNFR-related protein stimulation reverses cardiac allograft acceptance induced by CD40-CD40L blockade.

Authors:  Kenneth T Krill; Keri Csencsits-Smith; Sherri C Wood; Susan Faust; Guanyi Lu; D Keith Bishop
Journal:  Clin Dev Immunol       Date:  2013-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.